Rafael (NYSE:RFL) Announces Quarterly Earnings Results

Rafael (NYSE:RFL) posted its earnings results on Thursday. The company reported ($0.08) EPS for the quarter, FiscalAI reports. The company had revenue of $0.18 million for the quarter. Rafael had a negative return on equity of 40.19% and a negative net margin of 3,321.74%.

Rafael Trading Up 6.1%

Shares of RFL opened at $2.25 on Friday. Rafael has a 12 month low of $1.12 and a 12 month high of $2.65. The stock’s 50 day moving average is $1.37 and its two-hundred day moving average is $1.31. The firm has a market cap of $117.02 million, a P/E ratio of -3.31 and a beta of 0.54.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rafael has a consensus rating of “Sell”.

Institutional Trading of Rafael

Several institutional investors have recently bought and sold shares of RFL. Geode Capital Management LLC grew its holdings in Rafael by 72.9% in the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after purchasing an additional 190,179 shares during the period. Marshall Wace LLP acquired a new stake in Rafael in the second quarter valued at approximately $50,000. Cable Car Capital LP acquired a new stake in Rafael in the second quarter valued at approximately $173,000. Vanguard Group Inc. grew its holdings in Rafael by 10.5% in the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after purchasing an additional 133,024 shares during the period. Finally, Citadel Advisors LLC grew its holdings in Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after purchasing an additional 41,335 shares during the period. 11.30% of the stock is owned by institutional investors and hedge funds.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.